Mersana Therapeutics Inc
MRSN6.660USD
+0.060+0.91%
交易中 （美东）报价延迟15分钟
830.04M总市值
亏损市盈率 TTM
关于 Mersana Therapeutics Inc 公司
Mersana Therapeutics, Inc. 是一家临床阶段的生物制药公司，专注于开发抗体-药物偶联物 (ADC)，为具有重大未满足需求的癌症患者提供具有临床意义的益处。该公司开发了两个专有的差异化 ADC 平台：Dolasynthen 和 Immunosynthen。Dolasynthen 是其细胞毒性 ADC 平台，旨在生成位点特异性的均质 ADC。Immunosynthen 是其专有的干扰素基因刺激剂 (STING) 激动剂平台，旨在生成系统性给药的 ADC，可在表达抗原的肿瘤细胞和肿瘤驻留免疫细胞中局部激活 STING 信号。该公司的产品线还包括 XMT-1660（一种针对 B7-H4 的 Dolasynthen ADC，处于 I 期临床试验阶段）和 XMT-2056（一种针对人类表皮生长因子受体 2 (HER2) 新型表位的 Immunosynthen ADC），以及其他早期资产。
公司简介
公司代码MRSN
公司名称Mersana Therapeutics Inc
上市日期Jun 28, 2017
CEODr. Martin H. Huber, M.D.
员工数量102
证券类型Ordinary Share
年结日Jun 28
公司地址840 Memorial Dr
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02139
电话16174980020
网址https://www.mersana.com/
公司代码MRSN
上市日期Jun 28, 2017
CEODr. Martin H. Huber, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
23.93K
--
Dr. Timothy B. Lowinger, Ph.D.
Dr. Timothy B. Lowinger, Ph.D.
Senior Vice President, Chief Science and Technology Officer
Senior Vice President, Chief Science and Technology Officer
10.31K
+0.55%
Mr. Brian Deschuytner
Mr. Brian Deschuytner
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Chief Financial Officer, Chief Operating Officer, Senior Vice President
4.86K
+7.10%
Dr. Mohan Bala, Ph.D.
Dr. Mohan Bala, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
2.75K
+0.04%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Independent Director
Independent Director
663.00
--
Ms. Alejandra V. Carvajal, J.D.
Ms. Alejandra V. Carvajal, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Dr. Andrew A. F. Hack, M.D., Ph.D.
Dr. Andrew A. F. Hack, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin H. Huber, M.D.
Dr. Martin H. Huber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anna Protopapas
Ms. Anna Protopapas
Director
Director
--
--
Dr. Willard H. Dere, M.D.
Dr. Willard H. Dere, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
23.93K
--
Dr. Timothy B. Lowinger, Ph.D.
Dr. Timothy B. Lowinger, Ph.D.
Senior Vice President, Chief Science and Technology Officer
Senior Vice President, Chief Science and Technology Officer
10.31K
+0.55%
Mr. Brian Deschuytner
Mr. Brian Deschuytner
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Chief Financial Officer, Chief Operating Officer, Senior Vice President
4.86K
+7.10%
Dr. Mohan Bala, Ph.D.
Dr. Mohan Bala, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
2.75K
+0.04%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Independent Director
Independent Director
663.00
--
Ms. Alejandra V. Carvajal, J.D.
Ms. Alejandra V. Carvajal, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
收入明细
FY2025Q1
FY2024
暂无数据
地区USD
名称
营收
占比
United States
2.75M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Nextech Invest, Ltd.
9.68%
Bain Capital Life Sciences Investors, LLC
6.95%
The Vanguard Group, Inc.
6.72%
Schonfeld Strategic Advisors LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.97%
Other
64.57%
持股股东
持股股东
占比
Nextech Invest, Ltd.
9.68%
Bain Capital Life Sciences Investors, LLC
6.95%
The Vanguard Group, Inc.
6.72%
Schonfeld Strategic Advisors LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.97%
Other
64.57%
股东类型
持股股东
占比
Investment Advisor
33.96%
Hedge Fund
16.36%
Investment Advisor/Hedge Fund
13.97%
Venture Capital
5.28%
Individual Investor
1.59%
Research Firm
1.22%
Family Office
0.61%
Bank and Trust
0.09%
Pension Fund
0.07%
Other
26.84%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
344
3.65M
73.32%
-2.99M
2025Q1
381
91.14M
73.20%
-85.10M
2024Q4
376
108.41M
87.04%
-80.71M
2024Q3
381
121.20M
99.04%
-61.95M
2024Q2
378
118.97M
97.46%
-69.30M
2024Q1
377
122.29M
100.13%
-59.89M
2023Q4
366
116.96M
97.07%
-50.97M
2023Q3
372
116.93M
97.32%
-45.36M
2023Q2
374
120.10M
105.19%
-2.78M
2023Q1
353
114.45M
106.31%
-2.65M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Nextech Invest, Ltd.
12.07M
9.68%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
8.66M
6.95%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
8.38M
6.72%
+1.32M
+18.71%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
7.61M
6.11%
+5.49M
+259.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.44M
5.97%
-865.63K
-10.43%
Mar 31, 2025
AQR Capital Management, LLC
5.14M
4.13%
+5.12M
+27092.58%
Mar 31, 2025
Rock Springs Capital Management LP
3.81M
3.06%
+383.00K
+11.16%
Mar 31, 2025
VR Adviser, LLC
3.57M
2.87%
-6.68M
-65.16%
Mar 31, 2025
SilverArc Capital Management, LLC
3.09M
2.48%
+3.09M
--
Mar 31, 2025
Acadian Asset Management LLC
2.99M
2.4%
+2.99M
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
iShares Russell 2000 Value ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Avantis Responsible US Equity ETF
0%
Tema Oncology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Proshares Ultra Russell 2000
0%
iShares Morningstar Small-Cap ETF
0%
查看更多
iShares Core S&P Total U.S. Stock Market ETF
占比0%
Fidelity MSCI Health Care Index ETF
占比0%
Direxion Daily S&P Biotech Bull 3X Shares
占比0%
iShares Russell 2000 Value ETF
占比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0%
Avantis Responsible US Equity ETF
占比0%
Tema Oncology ETF
占比0%
Invesco Nasdaq Biotechnology ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Morningstar Small-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
